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Abstract
Objective: The 6-minute walk test is widely used to assess functional status in
neurological disorders. However, the test is subject to great inter-test variability due
to fluctuating motivation, fatigue and learning effects. We investigated whether
inter-test variability of the 6MWT can be reduced by heart rate correction.
Methods: Sixteen patients with neuromuscular diseases, including
Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy,
Charcot-Marie-Tooths, Dystrophia Myotonica and Congenital Myopathy and 12
healthy subjects were studied. Patients were excluded if they had cardiac
arrhythmias, if they received drug treatment for hypertension or any other medical
conditions that could interfere with the interpretation of the heart rate and walking
capability. All completed three 6-minute walk tests on three different test-days.
Heart rate was measured continuously.
Results: Successive standard 6-minute walk tests showed considerable learning
effects between Tests 1 and 2 (4.9%; P50.026), and Tests 2 and 3 (4.5%;
P50.020) in patients. The same was seen in controls between Tests 1 and 2 (8.1%;
P50.039)). Heart rate correction abolished this learning effect.
Conclusion: A modified 6-minute walk test, by correcting walking distance with
average heart rate during walking, decreases the variability among repeated 6-
minute walk tests, and should be considered as an alternative outcome measure to
the standard 6-minute walk test in future clinical follow-up and treatment trials.
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Introduction
The 6-minute walk test (6MWT) is a submaximal exercise test, which despite
pitfalls, is widely used to assess treatment efficacy or disease progression in
neurological diseases, because walking capability is a central function of life and
reflects an important functional capacity of daily living [1, 2]. However, the test is
subject to a high inter-test variability, related to fluctuating motivation, fatigue,
and learning effects [3–8]. There is great need for outcome measures in clinical
trials, which are sensitive enough to detect even small changes of function, and as
such, the 6MWT is rather insensitive in its present form.
Cardiac output (CO) is known to be linearly correlated to work load,
irrespective of fatigue and motivation, and since heart rate (HR) is a function of
CO (CO 5 stroke volume x HR) [9, 10], we hypothesized that a correction of the
6MWT distance by average HR can smooth out day-to-day variability of the test
due to motivation or fatigue on the day of testing, or due to a learning effect.
Moreover, reliability and feasibility of the 6MWT, for adult patients, has only
been validated in one other study of neuromuscular disorders (NMD) [2]. We,
therefore, wanted to test if the learning effect after repeated 6MWTs is present in a
broad group of patients with NMD, if their walking distance correlates with HR,
and if HR correction of the 6MWT can reduce inter-test variability.
Methods
Subjects
The study included 16 patients, recruited from our neuromuscular clinic, and 12
healthy subjects. All diagnoses in patients were verified by genetic testing. Some
had preferential proximal and other distal lower limb weakness (Table 1).
Inclusion criteria were; ability to walk 60 meters, and left ventricular ejection
fraction above 40%. Exclusion criteria were arrhythmias, drug treatment that
could affect blood pressure and HR, and other medical conditions that could
interfere with the interpretation of the HR and walking capability. The reason for
including a control group was to identify, if a learning effect for the 6MWT, which
has formerly been described in several studies of healthy subjects, was similarly
present in both controls and patients with neuromuscular disorders. Furthermore,
we wanted to investigate if a correlation between walked distances and mean HR
existed. And if it was present in both patients and controls, we wanted to test
whether HR correction was feasible in both patients and healthy controls. Oral
and written informed consent was obtained from all subjects, and the study was
approved by the Regional Committee on Health Research Ethics in Denmark.
Procedures
Each subject completed three 6MWTs, on three different test-days, one week
apart. On each test-day the test subjects performed one 6MWT according to the
American Thoracic Society guidelines (ATS) (Table 2) [1]. Subjects were asked to
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avoid heavy meals 2 h before testing, and caffeine, alcohol, and hard physical
exercise within the last 24 h. Before each test, subjects were told to walk as far as
possible during the 6 minutes, not to speak, that rests were allowed, but that they
should resume walking as soon as they were able. During the 6MWT, patients
were given feedback at the end of every minute with encouragement such as ‘‘you
are doing well’’. HR was measured continuously every second during walking, by
a pulse-watch (Polar, Heart rate monitor, Finland) (File S1, File S2), and the
mean of measured heart rate during each walking period was used for analysis.
For consistency, the same investigator conducted all tests.
Statistics
Results are expressed as means¡ standard deviations (SD), or average change in
percentage and range. Demographic data between patients and controls were
compared by an unpaired two-sample student’s t-test. A statistical significance of
differences between mean 6MWT distances was assessed by a one-way ANOVA of
repeated measures with a Greenhouse-Geisser correction. Pairwise comparisons of
the specific differences in the 6MWT distances were subsequently assed by the
Bonferroni post hoc test. Pearson’s Correlation was used to investigate whether
there was an association between walked distance and HR. Statistical significance
was defined by P value #0.05.
Table 1. Gene mutations and muscle strength in 16 patients with neuromuscular disorders.
MRC MRC MRC
Patient Disease Age Hip (F/E) Knee (F/E) Ankle (F/E)
1 LGMD2I 60 R(1/4); L (1/4) R(4/4); L(4/4) R(5/5); L(5/5)
2 LGMD2I 52 R(2/4); L (2/4) R(2/4); L (2/4) R(5/5); L(5/5)
3 LGMD2I 20 R(5/5); L(5/5) R(5/5); L(5/5) R(5/5); L(5/5)
4 LGMD2A 63 R(4/4+); L(4/4+) R(4/5); L(4/5) R(5/5); L(5/5)
5 DM 2 64 R(5/5); L(5/5) R(5/5); L(5/5) R(4/4+); L(4/4+)
6 DM2 39 R(5/5); L(5/5) R(5/5); L(5/5) R(5/5); L(5/5)
7 CMT1A 63 R(5/5); L(5/5) R(5/5); L(5/5) R(4-/5); L(4-/5)
8 CMT1A 47 R(5/5); L(5/5) R(5/5); L(5/5) R(4/5); L(4/5)
9 CMT1A 52 R(5/5); L(5/5) R(5/5); L(5/5) R(4-/5); L(4-/5)
10 CM 21 R(4/4); L(4/4) R(4/4); L(4/4) R(4/4); L(4/4)
11 CM 54 R(4-/4-); L(4-/4-) R(4-/4-); L(4-/4-) R(1/2); L(1/2)
12 FSH 60 R(5/5); L(5/5) R(5/5); L(5/5) R(5/5); L(5/5)
13 FSH 31 R(5/5); L(5/5) R(5/5); L(5/5) R(5/5); L(5/5)
14 FSH 50 R(5/5); L(5/5) R(5/5); L(5/5) R(4/5); L(4/5)
15 FSH 36 R(5/5); L(5/5) R(5/5); L(5/5) R(4/5); L(4/4)
16 FSH 46 R(5/5); L(4/5) R(5/5); L(5/5) R(4/5); L(4+/5)
Abbreviations: LMGD 5 Limb-girdle muscular dystrophy, DM 5 Myotonic dystrophy, CMT 5 Charcot-Marie-Tooth disease, CM 5 Congenital myopathy,
FSH 5 Facioscapulohumeral muscular dystrophy, MRC 5 Medical Research Council Scale, (F/E) 5 Flexion/Extension, R5 right, L5 left.
doi:10.1371/journal.pone.0114273.t001
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Table 2. Walked distance during each test for patients and controls.
Test 1 Test 2 Test 3
Patient Mean SD
1 420 419 424 421 2.6
2 189 186.2 199 191.4 6.7
3 735 754 780 756.4 22.4
4 315 323 318 318.7 4
5 515 549 557 540.3 22.3
6 343 356 368 355.7 12.5
7 498 614 720 610.7 111
8 484 515 553 517.3 34.6
9 434 448 468 450 17.1
10 678 654 680 670.7 14.5
11 531 559 567 552.3 18.9
12 611 571 659 613.7 44.1
13 646 743 795 728 75.6
14 535 572 577 561.3 22.9
15 538 561 527 542 17.3
16 305 334 329 322.7 15.5
Min 189 186.2 199
Max 735.3 754 795
Mean 486.1 509.9 532.6
SD 147.4 156.2 173.0
Control Test1 Test 2 Test 3
1 679 772 751.5 734.2 48.9
2 749 893.2 839 827.1 72.8
3 962 953 900 938.3 33.5
4 641 850 935 808.7 151.3
5 695 725 774 731.3 39.9
6 735 664 670 689.7 39.4
7 705 705 655 688.3 28.9
8 675 705 740 706.7 32.5
9 645 674 733 684 44.8
10 788 836 839 821 28.6
11 660 658 667 734.2 4.7
12 750 965 973 896 126.5
Min 641 658 655
Max 962 965 973
Mean 723,7 783,4 789,7
SD 87,9 112,3 107,3
doi:10.1371/journal.pone.0114273.t002
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All statistical analyses were performed using IBM SPSS statistical software
version 20.0, and Microsoft Excel version 14.4.3, 2011.
Results
Characteristics of the study population
Except for age, demographic data were comparable between patient and healthy
subjects (Table 3). Muscle affection was primarily proximal in LGMD patients,
distal in patients with CMT1A and FSHD, and diffuse in patients with congenital
myopathy and myotonic dystrophy type 2 (Table 1).
6MWT: Inter-test variation and effects of correcting with heart rate
(Figure 1)
A repeated measures ANOVA with a Greenhouse-Geisser correction determined
that mean walking distance differed significantly between time points for both
patients (F(1.335, 20.026) 58.262, P50.006) and controls (F(1.248, 13.727)
54.417, P50.048). Post hoc tests using Bonferroni correction for sequential
6MWTs showed a considerable learning effect in patients, with 24 m (4.9%;
P50.026) between Tests 1 and 2, and 23 m (4.5%; P50.020) between Tests 2 and
3. The same was seen in controls (59 m between Tests 1 and 2 (8.1%; P50.039)).
No significant difference was observed between Test 2 and Test 3 for controls.
Pearson’s Correlation showed that walking distance and HR correlated well (r
50.731; 95% confidence interval: 0.573–0.886, P#0.001) in the 28 subjects (
Figure 2). Thus, when correcting distance in 6MWT by HR, all day-to-day
variations were abolished (Figure 1B).
Discussion
This study shows that a 6MWT corrected for HR has much less inter-test
variability, and is therefore a more consistent outcome measure to assess walking
ability in NMDs and healthy subjects than a standard 6MWT. Thus, HR-adjusted
walking distance corrects day-to-day variation in the 6MWT, due to learning
effects, motivation, and fatigue. Such pitfalls are otherwise well acknowledged
limitations of the test in a number of diseases [10]. Our study also shows that a
learning effect is present in a wide range of different NMDs, similar to the learning
effect shown in earlier studies of other diseases [3–8], which cautions the use of
the standard 6MWT in uncontrolled trials of NMDs.
The reliability of the 6MWT in adult patients with NMD has only been
validated in patients with myotonic dystrophy type 1, in whom an increase in
walking distance was observed with repeated 6MWTs [2]. Practice tests were
therefore recommended.
The overall close correlation between HR and distance walked in the standard
6MWT was also found for repeated tests in individual subjects with the exception
Heart Rate Corrected 6-Minute Walk Test
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Table 3. Characteristics of patients and controls.
Patients Controls
n516 n512
Mean (SD) Min-Max Mean (SD) Min-Max
Sex (M/F) (7/9) (6/6)
Age (years) 47.4 (14.4)* 20–64 34.8 (14.5)* 20–67
Height (m) 173.3 (9.6) 158–187 175 (6.8) 166–189
Weight (kg) 75.2 (11.8) 57–100 73.8 (23.2) 53–235
BMI (kg/m2) 25.1 (3.5) 20.2–30.5 23.7 (5.5) 19.2–37.8
M5 male, F5 female, BMI 5 body mass index. *P,0.05.
doi:10.1371/journal.pone.0114273.t003
Figure 1. Distance walked with, and without heart rate correction. A. Mean distance walked in all 6-
minute walk tests, for both patients and controls. The graph shows the significant increases, marked by the p-
value, in mean walked distance among tests. B. Heart rate corrected 6-minute walk distance in all 6-minute
walk tests, for both patients and controls. No significant difference between walked distances was observed.
doi:10.1371/journal.pone.0114273.g001
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of three patients and two controls. There was no obvious explanation for the
absence of correlation in these subjects, but HR responses may have been
influenced by use of tobacco, alcohol or caffeine before experiments, although
subjects were told to refrain from such use. However, our results demonstrate that
in larger studies, a few patients in whom a coupling between HR and walking
distance is disturbed, will not distract from the main conclusion, that HR-
adjusted walking distance is a stronger outcome measure than a ‘‘raw’’ walking
distance. Nevertheless the HR-adjusted 6MWT should only be used in patients
without cardiac affection. Our findings can likely be extended to other diseases in
which the 6MWT is commonly used, as the source of day-to-day variation of the
test (learning effects, motivation, fatigue) is very similar across diseases. However,
studies are necessary to corroborate this in individual diseases. Heart rate is an
easily measured clinical parameter, and analysis of the linear correlation between
walked meters and mean measured HR can easily be obtained for follow-up
assessments and as endpoint in clinical trials, in which 6MWT is used as efficacy
parameter. 6MWT corrected by mean HR during the test (walked meters/mean
HR), likely can detect clinically meaningful changes in a trial, as indicated by a
longer distance walked at a similar HR on treatment or a similar distance walked
at a lower HR. However, this relationship should be confirmed in future
treatment studies, to verify that the HR-corrected 6MWT, which abolishes the
confounding factors from a learning effect, can also detect treatment effects.
Figure 2. Correlation between heart rate and 6-minute walk distance. The graph shows the Pearson’s
correlation between heart rate and walked distance for both patients and controls.
doi:10.1371/journal.pone.0114273.g002
Heart Rate Corrected 6-Minute Walk Test
PLOS ONE | DOI:10.1371/journal.pone.0114273 December 5, 2014 7 / 8
Conclusion
Our findings suggest that a heart rate-corrected 6MWT is a more accurate
outcome measure than the standard 6MWT, and should be considered as a future
outcome measure of walking capability.
Supporting Information
File S1. Continued measured heart rate data for controls.
doi:10.1371/journal.pone.0114273.s001 (XLSX)
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